| Literature DB >> 24500453 |
Doreen McClurg1, Paul Hilton, Lucia Dolan, Ash Monga, Suzanne Hagen, Helena Frawley, Lucy Dickinson.
Abstract
INTRODUCTION AND HYPOTHESIS: There is evidence that in nonsurgical populations, pelvic floor muscle training (PFMT) and lifestyle advice improves symptoms and stage of pelvic organ prolapse (POP). Some women, however, require surgery, after which de novo symptoms can develop or additional surgery is required due to recurrence. Robust evidence is required as to the benefit of perioperative PFMT in the postsurgery reduction of symptoms and POP recurrence. The aim of this study was to assess the feasibility of and collect pilot data to inform sample size (SS) calculation for a multicentre randomised controlled trial (RCT) of perioperative PFMT following surgical intervention for POP.Entities:
Mesh:
Year: 2014 PMID: 24500453 PMCID: PMC4057627 DOI: 10.1007/s00192-013-2301-x
Source DB: PubMed Journal: Int Urogynecol J ISSN: 0937-3462 Impact factor: 2.894
Fig. 1Consolidated Standards of Reporting Trials (CONSORT) flow diagram
Summary of prolapse-related quality of life (QoL) scores at baseline and 6 months for treatment (TG) and control (CG) groups (all centres)
| Measurement | TG baseline, mean (SD) | CG baseline, mean (SD) | TG, mean (SD) | CG, mean (SD) | Between-group difference in change, (95 % CI), |
|---|---|---|---|---|---|
POP-SS Lower scores indicate better QoL | 13.40 (6.57) | 13.44 (5.69) | 3.90 (4.54)
| 3.72 (3.89)
| (−2.561 to 2.192) −0.156 0.876 |
| ICIQ-UI; lower scores indicate better QoL | 6.21 (4.68) | 6.13 (6.62) | 2.75 (3.67)
| 3.32 (3.47)
| (−1.48 to 2.97) −0.050 0.96 |
| ICIQ-BS; lower scores indicate better QoL | 16.92 (6.08) | 13.55 (3.07) | 11.59 (3.83)
| 12.42 (3.38)
| (−1.26 to 2.93) −2.64 0.11 |
| SF-12; higher score indicates better QoL | 33.57 (3.55) | 35.14 (6.73) | 46.43 (13.35)
| 49.12 (19.12)
| (−6.97 to 12.35) 0.559 0.579 |
POP-SS Pelvic Organ Prolapse Symptom Score, ICIQ-BS International Consultation on Incontinence Questionnaire Bowel Symptom, SF-12 Short Form Health Survey of 12 items, SD standard deviation, CI confidence interval
Adherence to completion of outcome measure questionnaires
| All questionnaires | Treatment group | Control group | Newcastle ( |
|---|---|---|---|
| Baseline | 28 (100 %) | 29 (100 %) | 13/13; 14/14 |
| 6 months | 23 (82 %) | 25 (86 %) | 12/13; 12/14 |
| 12 months | 14 (50 %) | 13 (44 %) | 12/13; 11/14 |
Pelvic organ prolapse (POP) stage as measured using the POP Quantification (POP-Q) at baseline and 6 and 12 months
| Stage of Prolapse | Baseline | Baseline | 6 month | 6 month | 12 month | 12 month |
|---|---|---|---|---|---|---|
| TG ( | CG ( | TG ( | CG ( | TG ( | CG ( | |
| Stage 0 | 0 | 0 | 10 | 11 | 5 | 4 |
| Stage I | 2 (7 %) | 2 (7 %) | 4 | 2 | 1 | |
| Stage II | 18 (64 %) | 15 (57 %) | ||||
| Stage III | 5 (20 %) | 9 (34 %) |
TG treatment group, CG control group
Pelvic floor muscle assessment
| Measure | TG baseline | CG baseline | TG 6 months | CG 6 months | TG 12 months | CG 12 months |
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| mean (SD) | mean (SD) | mean (SD) | mean (SD) | mean (SD) | mean (SD) | |
| Power | 2.56 (0.935) | 2.81 (1.021) | 3.57 (0.646) | 2.87 (1.060) | 3.50 (0.654) | 2.36 (0.809) |
| Endurance (s) | 7.13 (3.123) | 6.6 (3.279) | 8.43 (2.441) | 7.30 (2.720) | 7.00 (2.453) | 7.27 (2.240) |
| Repetitions | 6.41 (2.501) | 5.88 (3.0470) | 7.93 (2.018) | 6.62 (2.329) | 10 (2.345) | 7.91 (2.256) |
| Hold with cough: Yes/N | 12/25 (48 %) | 13/26 (50 %) | 13/14 (92 %) | 10/15 (66 %) | 5/5 (100 %) | 3/5 (60 %) |
TG treatment group, CG control group, SD standard deviation
Summary of questionnaires at baseline and 6 and 12 months (Newcastle only)
| Measurement | Treatment group baseline | Control group baseline | Treatment group | Control group | Treatment group | Control group | Between-group difference: |
|---|---|---|---|---|---|---|---|
| 6 months | 6 months | 12 months | 12 months | 0–12 months | |||
| mean/SD | mean/SD | mean/SD | mean/SD | mean/SD | mean/SD | (95% CI), | |
| POP-SS | 13.38 (5.76) | 14.69 (5.40) | 3.27 (4.50) | 5.41 (5.96) | 2.45 (2.42) | 6.40 (3.40) | (1.35 to 6.75)
|
| ICIQ-UI | 6.30 (7.69) | 6.30 (4.47) | 3.54 (4.69) | 3.84 (3.69) | 1.30 (1.60) | 3.23 (3.60) | (−0.33 to 4.18)
|
| ICIQ-BS | 14.53 (5.36) | 13.92 (3.64) | 12.90 (5.02) | 12.85 (3.95) | 11.40 (4.52) | 11.38 (3.01) | (−4.22 to −3.00)
|
| SF-12 | 35.20 (0.92) | 34.83 (6.01) | 42.82 (3.68) | 40.20 (5.20) | 42.58 (3.60) | 35.70 (6.29) | (−11.34 to −2.43)
|
| PISQ | 42.69 (23.90) | 38.53 (19.91) | 36.23 (26.56) | 36.84 (22.69) | 31.07 (23.19) | 29.38 (17.76) | (−13.65 to 21.96)
|
POP-SS Pelvic Organ Prolapse Symptom Score, ICIQ-BS International Consultation on Incontinence Questionnaire Bowel Symptom, SF-12 Short Form Health Survey of 12 items, PISQ POP/Urinary Incontinence Sexual Questionnaire, SD standard deviation, CI confidence interval